Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03088605Phase 2Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Role: collaborator

NCT03833388Phase 2Completed

Study of TOP1630 for Dry Eye Syndrome

Role: lead

NCT03071081Phase 1Completed

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

Role: lead

NCT02888379Phase 2Completed

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

Role: lead

NCT02463045Phase 1Completed

Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

Role: lead

All 5 trials loaded